# International journal of clinical oncology

Source: https://onco.cc/journals/international-journal-of-clinical-oncology/  
OnCo record `international-journal-of-clinical-oncology` (Journal). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The official journal of the Japan Society of Clinical Oncology, publishing clinical trials and other clinical cancer research in English. Read by oncologists in Japan and internationally.

## Summary

International Journal of Clinical Oncology (IJCO) is the official journal of the Japan Society of Clinical Oncology and is published by Springer under a hybrid publishing model. Its aims welcome original and review papers on all aspects of clinical oncology reporting novel and timely investigations, encourage reports of clinical trials and give priority to high-quality clinical articles such as prospective randomised studies over retrospective ones; basic and translational studies are accepted only when they have obvious clinical significance, and society membership is not required to submit. Papers are peer reviewed by at least two referees and the Editors. The NLM Catalog records a start in 1996, publication for the society by Springer-Verlag Tokyo since 1998, six issues a year and MEDLINE indexing.

## Fields

- Kind: Journal
- Last checked: 2026-09-10
- Also known as: Int J Clin Oncol; IJCO
- Publisher: Springer (Springer Japan)
- Scope: clinical oncology
- Access: hybrid

## Sources

- Homepage: https://link.springer.com/journal/10147
- NLM Catalog: https://www.ncbi.nlm.nih.gov/nlmcatalog/9616295

## Connected records

- collections: [Japanese oncology guidelines (JSMO, JSCO and organ societies)](https://onco.cc/collections/jsmo-jsco-guidelines/), [PubMed & Europe PMC](https://onco.cc/collections/pubmed-europepmc/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Randomised trial](https://onco.cc/terms/randomised-trial/)
- key papers: [First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1](https://onco.cc/key-papers/paper-checkmate-227-int-j-clin-oncol-2023-update/), [Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors](https://onco.cc/key-papers/paper-nct05101096-int-j-clin-oncol-2024/)

---
JSON: https://onco.cc/api/v1/entities/international-journal-of-clinical-oncology.json